New maintenance treatment helps people with small-cell lung cancer live longer
☕ Includes a question for the family ↓
Lung cancerPart of a story we are following · 8 articles · See every update
If you have ever watched someone face lung cancer, you know how hard the small-cell type can be. Here is some good news. A new treatment added after the first round of care helped people with advanced small-cell lung cancer live much longer.
In a large trial, people who got the medicine tarlatamab on top of their usual maintenance treatment had a median survival of 21.1 months. Those on the usual treatment alone had 12.7 months. For a cancer with so few wins, that is a real step forward.
How the study worked
This was a phase 3 trial, the kind that tests a treatment in a large group. It enrolled 563 adults with extensive-stage small-cell lung cancer, meaning the cancer had spread. All of them had finished first-line chemotherapy plus immunotherapy and their cancer had not grown. By chance, 282 got tarlatamab plus durvalumab and 281 got durvalumab alone. The results were reported in the New England Journal of Medicine on Oct. 24, 2026, from a planned interim look at the data, in a trial where patients and doctors knew who got which treatment and which Amgen and AstraZeneca paid for.
What they found
Without the new treatment, people with this cancer typically live about 12 to 13 months. In this trial, the usual-treatment group matched that, at 12.7 months. The group that also got tarlatamab reached 21.1 months. “Median” means the middle point: half the people lived longer than that number.
The cancer also stayed under control longer. Median time before it grew or got worse was 7.4 months with tarlatamab and 1.9 months without it.
| Tarlatamab + durvalumab | Durvalumab alone | |
|---|---|---|
| Median survival | 21.1 months | 12.7 months |
| Median time before the cancer grew | 7.4 months | 1.9 months |
| Serious side effects (grade 3 or higher) | 46.8% | 40.6% |
Serious side effects were a bit more common with the combination, and the two groups were close. The most notable one was cytokine release syndrome, an immune reaction that can cause fever and flu-like symptoms. It showed up in nearly half the people on tarlatamab, and it was mostly mild or moderate. Care teams know how to watch for it.
What is tarlatamab?
Think of it as a matchmaker with two hands. One hand grabs a protein called DLL3 that sits on small-cell lung cancer cells. The other grabs a protein called CD3 on T cells, which are part of your immune system. Pulling the two together helps the T cells attack the cancer. Earlier research had already shown it helped people live longer when used as a second treatment. This trial shows it also works early, as part of maintenance care.
What you can do today
You may feel there is nothing for you to do, and that is fair. But news like this travels best through people. If someone you know is dealing with small-cell lung cancer, share this article with them or their family. If they have finished first-line treatment and their cancer has not grown, they can write down one question for their oncologist: “Is tarlatamab maintenance, or a clinical trial, an option for me?” The trial is listed on ClinicalTrials.gov as NCT06211036.
Talk about it at home
Our bodies have defense cells that can fight sickness, but cancer cells can be hard for them to spot. This new medicine works like a matchmaker. It holds a cancer cell in one hand and a defense cell in the other, so the defense cell knows what to attack.
Question for the table
The doctors flipped a coin, in a way, to decide who got the new medicine. How does that help them know the medicine was the reason people lived longer, and not just luck?
Keep exploring
Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.
Questions and answers
- What is tarlatamab?
- It is a medicine that links a protein on small-cell lung cancer cells to immune T cells, so the T cells can attack the cancer.
- How much longer did people live?
- Median survival was 21.1 months with tarlatamab plus durvalumab, compared with 12.7 months with durvalumab alone.
- Who was in the trial?
- 563 adults with extensive-stage small-cell lung cancer whose disease had not grown after first chemotherapy plus immunotherapy.
- What side effects did people have?
- Nearly half of those on tarlatamab had cytokine release syndrome, mostly mild or moderate. Serious side effects occurred in 46.8% versus 40.6% of people.
